PAS
FOLD

Park Avenue Securities’s Amicus Therapeutics FOLD Stock Holding History

Park Avenue Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,028
Closed -$123K – 1301
2024
Q4 		$123K Buy
+13,028
New +$135K ﹤0.01% 1449
2024
Q3 		– Sell
-14,513
Closed -$144K – 1407
2024
Q2 		$144K Buy
14,513
+1,355
+10% +$13.9K ﹤0.01% 1331
2024
Q1 		$155K Buy
13,158
+673
+5% +$8.61K ﹤0.01% 1335
2023
Q4 		$177K Buy
12,485
+1,961
+19% +$22.3K ﹤0.01% 1307
2023
Q3 		$128K Buy
+10,524
New +$136K ﹤0.01% 1237
2023
Q1 		– Sell
-10,527
Closed -$129K – 869
2022
Q4 		$129K Buy
+10,527
New +$119K ﹤0.01% 1165

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Park Avenue Securities's FOLD Position: Q1 2025 in Review

Park Avenue Securities sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 13,028 shares — an estimated $123K sold.

Park Avenue Securities first reported a position in FOLD in Q4 2022 and held it in 6 quarters. The position peaked at $177K in Q4 2023. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Park Avenue Securities reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Park Avenue Securities sold 13,028 Amicus Therapeutics shares in Q1 2025, an estimated $123K.
  • Park Avenue Securities first reported a position in Amicus Therapeutics in Q4 2022 and held it in 6 quarters.
  • Park Avenue Securities's Amicus Therapeutics position peaked at $177K in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Park Avenue Securities's 13F filing for Q1 2025, filed 14 Apr 2025.